Cdc25B Dual-specificity phosphatase inhibitors identified in a high-throughput screen of the NIH compound library

Assay and Drug Development Technologies

Volumn 7, Issue 3, 2009, Pages 250-265

  Johnston, Paul A ^a,b   Foster, Caleb A ^a   Tierno, Marni Brisson ^a   Shun, Tong Ying ^a   Shinde, Sunita N ^a   Paquette, William D ^a   Brummond, Kay M ^a   Wipf, Peter ^a   Lazo, John S ^a,b  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5,6 DI(FURAN 2 YL) 3 (PHENYLMETHYLSULFANYL) 1,2,4 TRIAZINE; 5,6 DI(FURAN 2 YL) 3 [2 (2 METHOXYETHOXY)ETHYLSULFANYL] 1,2,4 TRIAZINE; 5,6 DI(PHENYL) 3 (PHENYLMETHYLSULFANYL) 1,2,4 TRIAZINE; AMIDE; CATALASE; CELL CYCLE PROTEIN; CELL CYCLE PROTEIN 25; DUAL SPECIFICITY PHOSPHATASE 6; GLUTATHIONE; MERCAPTOETHANOL; MITOGEN ACTIVATED PROTEIN KINASE PHOSPHATASE 1; N [2,3 DI(FURAN 2 YL)QUINOXALIN 6 YL]AZEPANE 1 CARBOXAMIDE; PHOSPHATASE; QUINONE DERIVATIVE; TRIAZINE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CELL PROLIFERATION; CONTROLLED STUDY; DRUG MECHANISM; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME SPECIFICITY; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; IN VITRO STUDY; PROSTATE CANCER;

ANTINEOPLASTIC AGENTS; CDC25 PHOSPHATASES; CELL LINE, TUMOR; DRUG EVALUATION, PRECLINICAL; DUAL SPECIFICITY PHOSPHATASE 1; DUAL SPECIFICITY PHOSPHATASE 6; ENZYME INHIBITORS; FEMALE; HUMANS; HYDROGEN PEROXIDE; INDICATORS AND REAGENTS; MALE; MITOGEN-ACTIVATED PROTEIN KINASE PHOSPHATASES; NATIONAL INSTITUTES OF HEALTH (U.S.); OXIDATION-REDUCTION; SMALL MOLECULE LIBRARIES; UNITED STATES;

EID: 70350140452     PISSN: 1540658X     EISSN: None     Source Type: Journal    
DOI: 10.1089/adt.2008.186     Document Type: Article

References (51)

1. Boutros R, Dozier C, Ducommun B: The when and wheres of CDC25 phosphatases. CurrOpin Cell Biol 2006:18:185-191.
2. Boutros R, Lobjois V, Ducommun B: CDC25 phosphatases in cancer cells: key players? Good targets? Wot Rev Cancer 2007;7:495-507.
3. Contour-Galcera MO, Sidhu A, Prevost G, Bigg D, Ducommun B: What's new on CDC25 phosphatase inhibitors. Pharmacol Ther 2006 15:1-12.
4. Jiang ZX, Zhang ZY: Targeting PTPs with small molecule inhibitors in cancer treatment. Cancer Metastasis Rev 2008;27:263-272.
5. Kristjansdottir K, Rudolph J: Cdc25 phosphatases and cancer. Chem Biol 2004;11:1043-1051.
6. Rudolph J: Cdc25 phosphatases: structure, specificity, and mechanism. Biochemistry 2007;46:3595-3604.
7. Loffler H, Rebacz B, Ho AD, LukasJ, BartekJ, Kramer A: Chkl-dependent regulation of Cdc25B functions to coordinate mitotic events. Cell Cycle 2006;5:2543-2547.
8. van Vugt MATM, Bras A, Medema RH: Restarting the cell cycle when the checkpoint comes to a halt. Cancer Res 2005;65:7037-7040.
9. Bugler B, Quaranta M, Aressy B, Brezak MC, Prevost G, Ducommun B: Genotoxic-activated G2-M checkpoint exit is dependent on CDC25B phosphatase expression. Mol Cancer Ther 2006;5:1446-1451.
10. Cazales M, Boutros R, Brezak MC, Chaumeron S, Prevost G, Ducommun B: Pharmacologic inhibition of CDC25 phosphatases impairs interphase microtubule dynamics and mitotic spindle assembly. Mol Cancer Ther 2007;6:318-325.
11. Aressy B, Bugler B, Valette A, Biard D, Ducommun B: Moderate variations in CDC25B protein levels modulate the response to DNA damaging agents. Cell Cycle 2008;7:2234-2240.
12. Bansal P, Lazo JS: Induction of Cdc25B regulates cell cycle resumption after genotoxic stress. Cancer Res 2007;67:3356-3363.
13. Austin CP, Brady LS, Insel TR, Collins FS: NIH Molecular Libraries Initiative. Science 2004;306:1138-1139.
14. Inglese J, Auld DS, Jadhav A, Johnson RL, Simeonov A, Yasgar A, et al. Quantitative high-throughput screening: a titration-based approach that efficiently identifies biological activities in large chemical libraries. ProcNatl Acad Sci USA 2006;103:11473-11478.
15. Johnston PA, Soares KM, Shinde SN, Foster CA, Shun TY, Takyi HK, et al. Development of a simple 384-well colorimetric assay to quantify hydrogen peroxide generated by the redox cycling of compounds in the presence of reducing agents. Assay Drug Dev Technol 2008;6:505-518.
16. Johnston PA, Foster CA, Shun TY, Skoko JJ, Shinde S, Wipf P, et al.: Development and implementation of a 384-well homogeneous fluorescence intensity high-throughput screening assay to identify mitogen-activated protein kinase phosphatase-1 dual-specificity protein phosphatase inhibitors. Assay Drug Dev Technol 2007;5:319-332.
17. Johnston PA, Phillips J, Shun TY, Shinde S, Lazo JS, Huryn DM, et al. HTS identifies novel and specific uncompetitive inhibitors of the two-component NS2B-NS3 proteinase of West Nile virus. Assay Drug Dev Technol 2007;5:737-750.
18. Lazo JS: Roadmap or roadkill: a pharmacologist's analysis of the NIH Molecular Libraries Initiative. Mol interv 2006;6:240-243.
19. Tierno MB, Johnston PA, Foster C, Skoko JJ, Shinde SN, Shun TY, et al.: Development and optimization of high-throughput in vitro protein phosphatase screening assays. WotProfoc2007;2:1134-1144.
20. Lazo JS, Nemoto K, Pestell KE, Cooley K, Southwick EC, Mitchell DA, et al.: Identification of a potent and selective pharmacophore for Cdc25 dual specificity phosphatase inhibitors. Mol Pharmacol 2002;61:720-728.
21. Brisson M, Nguyen T, Wipf P, Joo B, Day BW, Skoko JS, et al.: Redox regulation of Cdc25B by cell-active quinolinediones. Mol Pharmacol 2005;68:1810-1820.
22. Brisson M, Nguyen T, Vogt A, Yalowich J, Giorgianni A, Tobi D, et al.: Discovery and characterization of novel small molecule inhibitors of human Cdc25B dual specificity phosphatase. Mol Pharmacol 2004;66:824-833.
23. Zhang JH, Chung TD, Oldenburg KR: A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen 1999;4:67-73.
24. Blower PE Jr, Cross KP, Fligner MA, Myatt GJ, Verducci JS, Yang C: Systematic analysis of large screening sets in drug discovery. Curr Drug Discov Technol 2004;1:37-47.
25. Alonso A, Sasin J, Bottini N, Friedberg I, Friedberg I, Osterman, A, et al.: Protein tyrosine phosphatases in the human genome. Cell 2004;117:699-711. (Pubitemid 38748887)
26. Bova MP, Mattson MN, Vasile S, Tarn D, Holsinger L, Bremer M, eta/.: The oxidative mechanism of action of ortho-quinone inhibitors of protein-tyrosine phosphatase alpha is mediated by hydrogen peroxide. Arch Biochem Biophys 2004;429:30-41.
27. Denu JM, Tanner KG: Specific and reversible inactivation of protein tyrosine phosphatases by hydrogen peroxide: evidence for a sulfenic acid intermediate and implications for redox regulation. Biochemistry 1998;37:5633-5642.
28. Kwon J, Lee SR, Yang KS, Ahn Y, Kim YJ, Stadtman ER, et al.: Reversible oxidation and inactivation of the tumor suppressor PTEN in cells stimulated with peptide growth factors. Proc Natl Acad Sci U S A 2004;101:16419-16424.
29. Lee SR, Yang KS, Kwon J, Lee C, Jeong W, Rhee SG: Reversible inactivation of the tumor suppressor PTEN by H202. J Biol Chem 2002;277:20336-20342.
30. Rhee SG: Cell signaling. H202, a necessary evil for cell signaling. Science 2006;312:1882-1883.
31. Rhee SG, Bae YS, Lee SR, Kwon J: Hydrogen peroxide: a key messenger that modulates protein phosphorylation through cysteine oxidation. SciSTKE 2000;2000(53):PE1.
32. Rhee SG, Chang TS, Bae YS, Lee SR, Kang SW: Cellular regulation by hydrogen peroxide. J Am Soc Nephrol 2003;14(8 Suppl 3):S211-S215.
33. Rhee SG, Kang SW, Jeong W, Chang TS, Yang KS, Woo HA: Intracellular messenger function of hydrogen peroxide and its regulation by peroxiredoxins. Curr Opin Cell Biol 2005;17:183-189.
34. Salmeen A, Andersen JN, Myers MP, Meng TC, Hinks JA, Tonks NK, et al.: Redox regulation of protein tyrosine phosphatase IB involves a sulphenyl-amide intermediate. Nature2003;423:769-773.
35. Seth D, Rudolph J: Redox regulation of MAP kinase phosphatase 3. Biochemistry 2006;45:8476-8487.
36. Sohn J, Buhrman G, Rudolph J: Kinetic and structural studies of specific protein-protein interactions in substrate catalysis by Cdc25B phosphatase. Biochemistry 2007;46:807-818.
37. Sohn J, Parks JM, Buhrman G, Brown P, Kristjansdottir K, Safi A, et al.: Experimental validation of the docking orientation of Cdc25 with its Cdk2-CycA protein substrate. Boichemestey 2005;44:16563-16573.
38. Brisson M, Foster C, Wipf P, Joo B, Tomko RJ Jr, Nguyen T, et al.: Independent mechanistic inhibition of cdc25 phosphatases by a natural product caulibu-g u lone. Mol Pharmacol 2007 ;71:184-192.
39. Cao S, Foster C, Lazo JS, Kingston DG: Four diterpenoid inhibitors of Cdc25B phosphatase from a marine anemone. Bioorg Med Chem 2005;13:5830-5834.
40. Cao S, Foster C, Lazo JS, Kingston DG: Sesterterpenoids and an alkaloid from a Thorectandra sp. as inhibitors of the phosphatase Cdc25B. Bioorg Med Chem 2005;13:5094-5098. (Pubitemid 41039969)
41. Cao S, Foster C, Brisson M, Lazo JS, Kingston DG: Halenaquinone and xesto-quinone derivatives, inhibitors of Cdc25B phosphatase from a Xestospongia sp. Bioorg Med Chem 2005;13:999-1003.
42. Kar S, Lefterov IM, Wang M, Lazo JS, Scott CN, Wilcox CS, et al.: Binding and inhibition of Cdc25 phosphatases by vitamin K analogues. Biochemistry 2003;42:10490-10497.
43. Peyregne VP, Kar S, Ham SW, Wang M, Wang Z, Carr Bl: Novel hydroxyl naphthoquinones with potent Cdc25 antagonizing and growth inhibitory properties. Mol Cancer Ther 2005;4:595-602.
44. Wipf P, Joo B, Nguyen T, Lazo JS: Synthesis and biological evaluation of cau-libugulonesA-E. Org Biomol Chem 2004;2:2173-2174.
45. Keinan S, Paquette WD, Skoko JJ, Beratan DN, Yang W, Shinde S, et al.: Computational design, synthesis and biological evaluation of para-quinone-based inhibitors for redox regulation of the dual-specificity phosphatase Cdc25B. Org Biomol Chem 2008;6:3256-3263.
46. Brisson M, Nguyen T, Wipf P, Joo B, Day BW, Skoko JS, et al.: Redox regulation of Cdc25B by cell-active quinolinediones. Mol Pharmacol 2005;68:1810-1820.
47. GuoJ, Parise RA, Joseph E, Lan J, Pan SS, Joo B, et al.: Pharmacology and antitumor activity of a quinolinedione Cdc25 phosphatase inhibitor DA3003-1 (NSC 663284). Anticancer Res 2007;27:3067-3073.
48. Lor LA, Schneck J, McNulty DE, Diaz E, Brandt M, Thrall SH, et al.: A simple assay for detection of small-molecule redox activity. J Biomol Screen 2007;12:881-890.
49. Eswaran J, von Kries JP, Marsden B, Longman E, Debreczeni JE, Ugochukwu E, et al.: Crystal structures and inhibitor identification for PTPN5, PTPRR and PTPN7: a family of human MAPK-specific protein tyrosine phosphatases. BoichemJ2006;395:483-491.
50. Chen U, Hecht SS, Peterson LA: Characterization of amino acid and glutathione adducts of cis-2-butene-1,4-dial, a reactive metabolite of furan. Chem Res Toxicol 1997;10:866-874.
51. Peterson L: Electrophilic intermediates produced by bioactivation of furan. Drug Metab Rev 2006;38:615-626.